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Background: Many Gram-negative bacteria rely on a type VI secretion system (T6SS) to infect eukaryotic cells or to
compete against other microbes. Common to these systems is the presence of two conserved proteins, in Vibrio
cholerae denoted VipA and VipB, which have been shown to interact in many clinically relevant pathogens. In this
study, mutagenesis of a defined region within the VipA protein was used to identify residues important for VipB
binding in V. cholerae O1 strain A1552.
Results: A dramatically diminished interaction was shown to correlate with a decrease in VipB stability and a loss of
hemolysin co-regulated protein (Hcp) secretion and rendered the bacterium unable to compete with Escherichia
coli in a competition assay.
Conclusions: This confirms the biological relevance of the VipA-VipB interaction, which is essential for the T6SS
activity of many important human pathogens.
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The type VI secretion system (T6SS) is a recently discov-
ered mechanism in Gram-negative bacteria that targets se-
creted proteins to eukaryotic as well as prokaryotic cells
[1,2]. Like type III and type IV secretion systems (T3SS
and T4SS), the T6SS mediates the contact-dependent
translocation of effector substrates directly into the recipi-
ent cell [3]. Although the genetic contents and orga-
nization may vary, 13 core subunits of T6SSs have been
recognized [4]. Two of these are highly conserved [5], and
we have demonstrated that the interaction between these
proteins occurs in a range of clinically important patho-
gens, including Vibrio cholerae, Francisella tularensis,
Salmonella enterica, Escherichia coli, Pseudomonas aeru-
ginosa, and Yersinia pseudotuberculosis [6]. Since many of
these proteins could also bind to cognate partners from
other bacteria, the mechanism behind complex formation* Correspondence: jeanette.broms@climi.umu.se
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reproduction in any medium, provided the orappears highly conserved. Moreover, a region encom-
passing a putative and conserved alpha-helix present in all
of the VipA homologues of the 6 aforementioned bacteria
was shown to be important for binding to their cognate
partner protein [6]. Even subtle amino acid substitutions
within this domain were found to result in essentially null
mutant phenotypes for F. tularensis, neutralizing its ability
to escape from the phagosomes and, thus, its ability to
replicate within the cytosol of infected macrophages
and rendering it avirulent [6]. The VipA-binding do-
main of VipB proteins has been less characterized, but
may reside within the N-terminus based on recent work
in Burkholderia cenocepacia. The same region was also
shown to be necessary for the T6SS activity of B.
cenocepacia [7].
In V. cholerae, VipA/VipB have been shown to form fila-
ments that structurally resemble bacteriophage T4 con-
tractile tail sheaths and these were quickly disassembled
by ClpV, an AAA+ traffic ATPase family protein [8-10].
The tubules were shown to cycle between assembly, quick
contraction, disassembly, and re-assembly, suggesting that
the sheath may energize the translocation of substrates by
a phage tail-like contraction mechanism [8]. The impor-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Alanine point mutants generated within α-helix 2 of
VipA. Shown is the amino acid sequence of residues 103–127
predicted to form α-helix 2 within VipA of V. cholerae strain A1552 as
well as the homologous region within IglA of F. tularensis LVS,
according to Psipred (http://bioinf.cs.ucl.ac.uk/psipred/). A deletion
within the first part (Δ104-113) of the α-helix abolishes VipA’s ability
to bind to VipB in both B2H and Y2H systems (−), while deletions
within the second part (Δ114-123) results in a VipA variant that
retains VipB binding in the Y2H system, but not in the B2H system
(+/−). Amino acids that were replaced with alanine in VipA are
indicated by closed triangles. Residues in F. tularensis IglA that
previously were mutated and shown to contribute to efficient IglB
binding are indicated also by closed triangles [6].
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tein (Hcp) has been demonstrated in both V. cholerae V52
and P. aeruginosa [9,11].
In most T6SSs, Hcp and valine-glycine repeat protein
G (VgrG) are exported by the secretion machinery
under normal laboratory cultural conditions. This is
not the case for V. cholerae O1 strain N16961, and
therefore it was suggested that the T6SS of V. cholerae
O1 strains was functionally inactive [12]. Our recent
studies showed, however, that the T6SS of V. cholerae
O1 strains can be activated when the bacteria are
grown under high osmolarity conditions, resulting in
the secretion of Hcp into the culture medium [13]. In
the same study, Hcp secretion was shown to require
the presence of VipA [13].
Here, residues within the previously identified VipB-
binding domain of VipA (aa 104–113) [6] were ex-
changed to alanine as a means to identify key residues
important for the interaction. To determine the bio-
logical consequences of a diminished VipA-VipB inter-
action in V. cholerae O1 strain A1552, the mutants
were assessed for their ability to bind to and stabilize
VipB, promote secretion of Hcp, and compete against
E. coli in a competition assay.
Results
Substitutions within the large α-helix of VipA negatively
impacts on VipA/VipB complex formation
To analyze the V. cholerae VipA-VipB interaction in detail,
we undertook a mutagenesis-based approach. Our previ-
ous results using a yeast 2-hybrid assay (Y2H) showed that
a deletion within the first part of the conserved α-helical
domain of VipA (mutant Δ104-113) abolished its binding
to VipB [6], while a deletion within the second part (mu-
tant Δ114-123) did not (Bröms, unpublished) (Figure 1).
To validate these results by an independent approach, we
here used an E. coli bacterial 2-hybrid assay (B2H) for
which the amount of β-galactosidase production is directly
proportional to the strength of a protein-protein inter-
action [14]. Similar to the positive control MglA-SspA [15],
VipA and VipB were found to interact efficiently in this
system (Figure 2A). Deletions within the conserved α-
helical domain of VipA (mutants Δ104-113 and Δ114-123)
abolished its interaction to VipB in B2H (Figures 1 and
2A), suggesting that residues within region 104–123
contribute to VipB binding. To identify the key residues
important for this interaction, we generated alanine substi-
tutions, focusing on the first part of the putative α-helix
(residues 104–113), since this region was shown to be cru-
cial for VipB binding regardless of the protein-protein
interaction assay used (Figure 1). Importantly, according to
Psipred V2.5 (http://bioinf.cs.ucl.ac.uk/psipred/), none of
the substitutions were predicted to affect the stability of
the α-helix. Of the vipA substitution mutants generated,several were shown to exhibit small but consistent defects
in VipB binding, especially mutants D104A, V106A,
V110A, and L113A (Figure 2A). Importantly, V110A cor-
responds to the V109A substitution within F. tularensis
IglA, which rendered F. tularensis unable to escape from
phagosomes, grow within host cells and to cause disease
in mice [6]. By combining two or more of the substi-
tutions that had a negative impact on VipB binding, an
additive effect was observed. Thus, the double mutants
V110A/L113A and D104A/V106A, the triple mutant
D104A/V106A/V110A and the quadruple mutant D104A/
V106A/V110A/L113A were all essentially unable to bind
VipB and produced β-galactosidase levels similar to the
negative vector control (Figure 2A). Importantly, all VipA
mutant alleles were produced at similar levels in the B2H-
reporter strain KDZif1ΔZ, which rules out the possibility
that variations in protein levels may account for the differ-
ences in VipB-binding (Figure 2B). VipA mutants that
appeared not to bind VipB showed marked VipB instabi-
lity and essentially no protein was detected by Western
blot analysis (Figure 2B).
To validate the interaction data by an independent ap-
proach, we selected some of the VipA mutants and
tested them for binding to VipB in the Y2H system using
two independent reporter genes: lacZ, which allows us
to compare the relative strength of the VipA-VipB inter-
actions by quantification of β-galactosidase activity, and
MEL1, which in the case of a positive interaction and in
the presence of the substrate X-α-Gal will promote blue
color development. According to both reporters, the de-
letion mutant Δ104-113, the double mutant V110A/
L113A and the quadruple mutant D104A/V106A/
V110A/L113A were all essentially unable to bind VipB
Figure 2 Bacterial two-hybrid analysis of protein-protein interactions involving VipA and VipB. (A) Contact between VipB and wild-type or
mutant VipA, fused to Zif and to the ω subunit of E. coli RNAP respectively, induces transcription from the lacZ promoter of the E. coli reporter
strain KDZif1ΔZ, resulting in β-galactosidase activity. As a positive control, MglA-Zif and SspA-ω was used while the negative control corresponds
to empty vectors. Shown is the mean β-galactosidase activity ± standard deviation in Miller units produced from 3 independent experiments
where two independent transformants were tested on each occasion. Data was subjected to a student’s 2-sided t-test to determine whether the
β-galactosidase activity produced by a VipA mutant was significantly different from that of wild-type VipA (*, P < 0.05; ***, P < 0.001). (B) To
determine levels of VipA mutants (upper panel) or VipB (lower panel), B2H cultures were pelleted and equivalent amounts were separated by
SDS-PAGE and analyzed by Western blot using polyclonal antibodies recognizing VipA or VipB. The experiment was repeated twice.
Bröms et al. BMC Microbiology 2013, 13:96 Page 3 of 12
http://www.biomedcentral.com/1471-2180/13/96and produced α-and β-galactosidase levels similar to the
negative vector control, while the double mutant D104A/
V106A and the triple mutant D104A/V106A/V110A both
showed intermediate binding (Table 1 and data not
shown). The less sensitive MEL1 reporter assay did not
detect any obvious binding defects for single mutants
D104A, V106A or V110A (data not shown), while the
lacZ reporter revealed a weak binding defect for both
V106A and V110A mutants (Table 1). Thus, overall, the
Y2H data confirms the results from the E. coli B2H assay.
Recently, we have shown that temperature and salinity
influences the activity of the T6SS of V. cholerae O1
strain A1552 [13]. To determine whether salt and/or
temperature also influence(s) the interaction of VipA
and VipB, we compared the strength of the interaction
in the B2H assay when E. coli was grown under different
salt and temperature conditions. The results suggest that
E. coli grown in Luria Broth (LB) supplemented with
additional NaCl (high salt) over night, generally producehigher β-galactosidase activity than if grown in low salt
(i.e. normal LB) (Figure 3). This suggests that a high
concentration of salt is beneficial for the VipA-VipB
interaction.
Mutating the VipB-interaction site of VipA leads to
unstable VipB and essentially abolishes Hcp secretion
Previously, Bönemann et al. have shown that VipA is es-
sential for secretion of Hcp as well as production of
VipB in V. cholerae non-O1 non-0139 strain V52 [9].
The latter was assumed to be a consequence of de-
creased VipB stability and, thereby, lower amounts of
the VipA/VipB complex. We have recently shown that
VipA is required for secretion of Hcp also in V. cholerae
O1 strain A1552 [13]. To investigate if any of our vipA
deletion or substitution mutants resulted in diminished
Hcp secretion and/or VipB production, we expressed
them as C-terminal His6 tagged variants from the ptac
promoter of pMMB66EH in an A1552 vipA null mutant




Activation domain Relative β-gal
activity
VipB None 0.5 ± 0.1% ***
VipB VipA 100.0 ± 5.8%
VipB VipA Δ104-113 1.0 ± 0.2% ***
VipB VipA D104A 92.7 ± 4.1%
VipB VipA V106A 92.4 ± 3.4% *
VipB VipA V110A 74.6 ± 3.4% ***
VipB VipA D104A/V106A 64.1 ± 10.7% *
VipB VipA V110A/L113A 1.1 ± 0.3% ***
VipB VipA D104A/V106A/V110A 48.8 ± 2.0% ***
VipB VipA D104A/V106A/V110A/L113A 1.0 ± 0.2% ***
VipA mutants fused to the GAL4 activation domain of plasmid pGADT7 were
co-transformed with VipB on the GAL4 DNA-binding domain pGBKT7 into the
S. cerevisiae reporter strain Y187. Activation of the lacZ reporter from 4
independent experiments where duplicate transformants were tested on each
occasion was determined and expressed as % mean β-galactosidase activity ±
SEM relative to the activity of the wild-type protein. A Student’s 2-sided t-test
was used to determine whether the differences observed were statistically
significant (*, P < 0.05; ***, P < 0.001).
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identically to non-tagged VipA in all analyses performed
(data not shown). By immunoblot analyses, we could con-
firm that all of the mutant strains expressed Hcp at levels
similar to the parental strain (Figure 4, top panel), but like
the vipA null mutant, some did not secrete Hcp into theFigure 3 The influence of salt and temperature on the VipA-VipB inte
leads to β-galactosidase activity, which is influenced by the growth tempe
mean β-galactosidase activity ± standard deviation in Miller units produced
tested on each occasion. The temperatures tested were 37°C (High) or 23°C
whether the β-galactosidase activity produced at any given condition was
standard assay conditions (85 mM NaCl, 37°C) (*, P < 0.05; **, P < 0.01; ***, Pculture medium. These corresponded to the deletion
mutants Δ104-113 and Δ114-123, as well as the multi-
ple substitution mutants V110A/L113A, D104A/V106A,
D104A/V106A/V110A and D104A/V106A/V110A/L113A
(Figure 4). The same mutants that failed to secrete Hcp
also failed to support stable production of VipB (Figure 4),
suggesting that there is a strong correlation between the
ability to secrete Hcp and the ability to produce stable
VipB in V. cholerae. When expressed together with VipB
in E. coli, the same VipA mutants also failed to support
stable VipB (compare Figures 2B and 4), demonstrating
that the same mechanisms of degradation exist in these
closely related species.
Importantly, Hcp secretion as well as VipB production
was efficiently restored upon expression of wild-type VipA
in trans (Figure 4). To determine whether the drastic phe-
notypes of some of the mutants could be explained by a
reduction in VipA stability, we used immunoblot analysis
and commercially available anti-His antibodies. By this ap-
proach, reduced levels of mutants Δ104-113, D104A and
E112A were consistently detected (Figure 4). Of these,
only Δ104-113 exhibited a null mutant-like phenotype
with respect to Hcp secretion and VipB production. No
obvious reduction in the total protein levels of any of the
other mutants exhibiting a null phenotype was observed
(Figure 4). To further analyze the stability of the VipA mu-
tants, we used a protein stability assay. The ΔvipA mutant
or ΔvipA expressing wild-type or mutated vipA in trans
were grown in LB overnight and subcultured into fresh
medium supplemented with IPTG to induce VipAraction. The VipA-VipB interaction in the reporter strain KDZif1ΔZ
rature as well as the NaCl concentration of the medium. Shown is the
from two experiments where two independent transformants were
(Low). Data was subjected to a student’s 2-sided t-test to determine
significantly different from that produced by KDZif1ΔZ grown under
< 0.001).
Figure 4 The influence of vipA mutations on VipB synthesis and Hcp synthesis/secretion. Deletion mutant alleles (lanes c-d), wild-type
(lane e) or substitution mutant alleles (lanes f-r) of vipA were expressed from the ptac promoter of pMMB66EH in a vipA null mutant background.
Hcp protein contained in the pellet fraction or secreted to the culture medium was separated by SDS-PAGE and identified by immunoblot
analysis using antiserum specific for Hcp. For detection of intrabacterial VipB and VipA, anti-VipB and anti-His antisera were used respectively. The
experiment was repeated at least three times and a representative example is shown.
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novo protein synthesis, bacteria were collected at different
time points and subjected to immunoblotting with anti-
sera recognizing His6 (i.e. VipA) or VipB. In ΔvipA ex-
pressing wild-type VipA in trans, both VipA and VipB
were very stable over a period of 240 min (Figure 5, top
panel). In contrast, in the non-complemented ΔvipA mu-
tant, VipB was barely detected in the time zero sample.
We also expressed His6-tagged VipB in ΔvipA or ΔvipB
mutant backgrounds and used anti-His antibodies to de-
termine VipB stability. The overall levels of VipB were sig-
nificantly lower in the ΔvipA strain, which was also
reflected by a decrease in VipB stability over time after
chloramphenicol addition (data not shown). In order to
understand the effects of VipA on VipB, we also analyzed
transcriptional stability of the vipA mutant, however, it
produced vipB transcripts at levels similar to the parental
strain A1552, -1.77 ± 0.68 (P = 0.17). Thus, the extreme
instability of VipB in the absence of VipA is most likely
due to degradation by endogenous proteases. Similar re-
sults have also been found for homologous IglA/IglB of F.
tularensis [6]. As already observed upon analyzing the pel-
let samples (above), mutant Δ104-113 was significantly
less stable also in the protein stability assay; it did not sup-
port VipB stability and had essentially disappeared
120 min after stopping de novo protein synthesis. In com-
parison to wild-type VipA, some of the point mutants
appeared less stable over time, especially D104A and
E112A, although this did not affect VipB stability
(Figure 5). In contrast, none of the double, triple, or quad-
ruple mutants appeared to be affected for VipA stability;
still, VipB was very unstable in these mutant backgrounds
(Figure 5). Thus, the dramatic phenotypes exhibited by
some of the vipA substitution mutants clearly cannot be
ascribed to a decrease in VipA protein stability.VipA/VipB complex formation influences the ability of
V. cholerae to compete with E. coli
Lately, type VI secretion (T6S) has been shown to play
an important role in interbacterial interactions, more
specifically in bacterial killing and competition [16-20].
For example, V. cholerae V52 uses its T6SS to efficiently
kill E. coli [21], which in turn requires most of the T6S
genes including vipA and vipB [20]. V. cholerae A1552
also uses T6S to compete with E. coli, although it does
not exert the massive T6S-mediated killing exhibited by
strain V52 [13]. To investigate the ability of the A1552
vipA mutants to compete with E. coli, we used a previ-
ously established competition assay that involves mixing
V. cholerae and E. coli MC4100, coculturing them on fil-
ters on agar plates at T6SS inducing conditions (i.e. high
salt, 37°C) for 5 h, and then recovering the number of
surviving target cells [13]. In addition to parental A1552
and ΔvipA, two categories of vipA mutants were used in
the assay: 1) single substitution mutants D104A, V106A,
V110A and L113A, which all showed slightly decreased
binding to VipB, although without any obvious defects
in VipB stability or Hcp secretion, and 2) multiple
substitution mutants D104A/V106A, V110A/L113A,
D104A/V106A/V110A and D104A/V106A/V110A/L113A,
which all showed null phenotypes with respect to VipB
binding, VipB stability and Hcp secretion. When E. coli
was cocultured with parental A1552, there was a 2 log10
drop in the number of viable E. coli cells recovered com-
pared with results for cultures inoculated with medium
alone (Figure 6). However, since the numbers of viable E.
coli never dropped below the initial inoculum, this sug-
gests that A1552, in contrast to the highly bactericidal
strain V52, may not be able to effectively kill the target
cells. This may likely be explained by the observation that
V52, in contrast to A1552, encodes a constitutively active
Figure 5 Stability analysis of various VipA mutants and their effect on VipB stability. Left panel: The intrabacterial stability of His6-tagged
VipA mutants was examined. At time 0, chloramphenicol was added to stop new protein synthesis. Samples from pelleted bacteria were taken at
different time points, and the amount of VipA protein was detected by western blot using anti-His antibodies. Right panel: The impact on VipB
expression/stability exhibited by the various vipA mutants was investigated by western blot using anti-VipB antibodies.
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fector proteins [12]. Using the identical set-up, V52 was
shown to efficiently kill E. coli, as the initial bacterial num-
bers dropped by > 1,000-fold (data not shown). The bac-
terial competition exerted by strain A1552 was shown to
depend on a functional T6SS, since the number of E. coli
increased by ~ 1.5 log10 when cocultured with the ΔvipA
mutant compared to parental A1552 (Figure 6). This dif-
ference was consistent between all experiments, but was
absent if V. cholerae was grown under non-T6S inducing
conditions (LB with 85 mM NaCl) or if a Δhcp mutant of
A1552 was used ([13] and data not shown). By expressing
wild-type vipA in trans, or any of the category 1 mutants
D104A, V106A, V110A or L113A, the numbers of E. coli
dropped to levels similar to that induced by A1552,
suggesting that competition was more or less restored.
Still, when compared to the wild-type protein, a small but
consistent reduction in the competitive ability was ob-
served for mutants D104A (P < 0.001), as well as V110A
and L113A (both P < 0.01). In contrast, none of themultiple substitution mutants (category 2) could compete
with E. coli and hence behaved indistinguishably from the
ΔvipA mutant (Figure 6). Importantly, all V. cholerae
strains tested exhibited similar growth when cultivated
in vitro in LB (data not shown). Thus, the ability to secrete
Hcp and efficiently bind/stabilize VipB is a prerequisite for
the ability of A1552 to compete with E. coli and this in
turn depends on key residues located within the con-
served α-helix of VipA.
VipA interacts with the N-terminus of ClpV in the yeast
two-hybrid assay
Recently, VipA/VipB was shown to form tubular,
cogwheel-like structures that are converted by a
threading activity of ClpV into small complexes [9,10].
The N-domain of ClpV (residues 1–178) was shown to
mediate the binding to the VipA/VipB complex, and it
was suggested that the primary contact between this
complex and the N-domain is mediated by VipB [9].
Recently, Pietrosiuk et al. identified a ClpV recognition
Figure 6 An intact VipA-VipB interaction is important for the ability of V. cholerae A1552 to compete with E. coli. V. cholerae parental
strain A1552, ΔvipA and ΔvipA expressing wild-type VipA or mutated variants thereof were mixed (3:1) with E. coli MC4100 and incubated under
T6SS-inducing conditions (340 mM NaCl, 37°C) on filters. After 5 h of incubation, the filters were resuspended in PBS, serially diluted and spread
on E. coli selective plates in triplicates. Shown is the number of surviving E. coli (log10) from one representative experiment out of four. The inoculum
control shows the starting number of E. coli prior to the 5 h incubation, while the LB control shows the number of E. coli obtained after 5 h of
incubation in the absence of V. cholerae. The ability of a strain to compete with E. coli was compared with that of ΔvipA (** P < 0.01; *** P < 0.001).
The experiment was repeated 4 times.
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VipB interactions require the oligomeric state of both
proteins [10].
To study the interaction between ClpV and VipA-VipB
in more detail, we used the B2H- and the Y2H systems.
While B2H did not reveal any interactions between ClpV
and VipA (data not shown), an interaction between
VipA and the ClpV N-terminus (aa 1–178) was observed
in Y2H, resulting in the activation of the reporter genes
ADE2 and HIS3 at 25°C (Figure 7). The interaction was
completely abolished at 37°C, suggesting that it was
weak (data not shown). The interaction did not occur if
full-length ClpV was used, which may be a consequence
of the rather low expression of the latter construct (data
not shown). In addition, also the VipA homologues
PA2365 of P. aeruginosa (30% id to VipA) and
YPTB1483 of Y. pseudotuberculosis (41% id to VipA)
were shown to interact with the N-domain of V. cholerae
ClpV in yeast, however the interaction was noticeably
stronger, as it resulted in more prominent growth on
medium lacking histidine (Figure 7). The ClpV inter-
action did not require an intact VipB-interaction site,
since all of VipA Δ104-113, PA2365 Δ109-118 and
YPTB1483 Δ105-114, carrying deletions within α-helix
H2 [6], maintained their ClpV-interacting ability. Thus,
similar to the VipA-VipB interaction, also the VipA-ClpV
interaction may be conserved among T6S-containing spe-
cies. Moreover, the ClpV- and VipB-interaction sites
within the VipA proteins appear distinct. No interaction
between ClpV and VipB or its homologues could be
detected in either the B2H or the Y2H system (Figure 7
and data not shown).Discussion
V. cholerae depends on virulence factors like toxin co-
regulated pili (TCP) and cholera toxin (CT), to cause the
severe, life-threatening diarrheal disease, cholera [22,23].
A T6SS was recently implicated as an additional viru-
lence determinant of V. cholerae that is required for Hcp
secretion [12], for killing of amoeba and bacteria [12,20],
and also contributes to the inflammatory diarrhea in in-
fant mice and rabbits [24,25]. The large majority of
T6SS genes (12 out of 17), including VipA, VipB, ClpV,
VasF and VasK, are required for Hcp secretion, killing of
amoeba and bacteria and are predicted to encode struc-
tural T6SS components [9,12,20]. In addition, regulatory
proteins, VasH and VCA0122 [12,20], as well as effector
proteins, VgrG-1 and possibly VCA0118, have also been
identified [20,24,26,27].
By using an in silico approach analyzing the F.
tularensis VipA-VipB homologues, we previously identi-
fied four distinct α-helices (H1 to H4) in the VipA
homologue, IglA [6]. Interestingly, all of these helices
were found to be essential for growth of F. tularensis in
macrophages. While H3 and H4 were located in regions
of little importance for VipB binding, H1 and H2 over-
lapped with regions crucial for the interaction. Although
the F. tularensis T6SS is phylogenetically only distantly
related to other T6SSs, domains structurally very similar
to the four helices with the same specific locations were
predicted in an extensive number of homologues of
other Gram-negative bacteria. These structural simi-
larities also correlated to a functional relationship, as
evidenced by our demonstration of both native and he-
terologous interactions between the A-B homologues of
Figure 7 VipA interacts with the N-terminus of ClpV (ClpV N´)
in yeast. VipA, VipB and their homologous proteins from P. aeruginosa
PA01 (locus tag PA2365 and PA2366 respectively) or Y. pseudotuberculosis
IP 32953 (locus tag YPTB1483 and YPTB1484 respectively) were fused to
the GAL4 activation domain of plasmid pGADT7 and co-transformed
with ClpV (aa 1–178) on the GAL4 DNA-binding domain pGBKT7 into
the S. cerevisiae two-hybrid assay reporter strain AH109. A positive
interaction will result in the activation of the two independent reporter
genes, ADE2 and HIS3, to permit growth of yeast on minimal medium
devoid of adenine and histidine respectively recorded after day 5 at
25°C. Results reflect trends in growth from two independent experiments
in which several individual transformants were tested on each occasion.
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ther low levels of amino acid identities. Thus, the evi-
dence indicates that the H2, and possibly also the H1,
helices are essential for the formation of the A/B com-
plex due to the strong preservation of these structures
despite different evolutionary origins.
In view of this background, we wanted to further
characterize the previously identified interaction of the
H2 helix of VipA using a targeted mutagenesis approach.
Residues within the conserved α-helix of VipA were ex-
changed to alanine and the resulting mutants tested in a
B2H system. By this approach, several residues import-
ant for the VipB interaction were identified, i.e. D104,
V106, V110, P111 and L113. Interestingly, out of these,V106, V110 and L113 were homologous to the residues
V105, V109 and I112 respectively of the F. tularensis
homologue IglA, which when mutated resulted in di-
minished IglB binding [6]. This confirms that the mech-
anism behind A/B complex formation is conserved in
distantly related pathogens. The small but consistent de-
fect in VipB-binding, however, had no visible effect on
VipB expression/stability or Hcp secretion in vitro, al-
though mutants D104A, V110A and L113A were all less
efficient at competing with E. coli when tested in a bac-
terial competition assay. These results resemble those
obtained with IglA, for which mutants V109A and
L115A showed a defect in IglB binding, but not on IglB
stability, yet both mutants were completely unable to
grow within host cells and were also avirulent in mice
[6]. Thus, even subtle defects in the A-B interaction have
drastic impact on the competitive ability of T6S-
containing pathogens, as well as on their ability to suc-
cessfully infect host cells. By combining two or more of
the single substitutions that resulted in a defect in VipB-
binding, an additive effect was apparent; the ability to
interact with VipB binding was poor or abolished in both
B2H and Y2H systems, and similarly to a vipA null mu-
tant, these multiple substitution mutants were unable to
support stable VipB, Hcp secretion, and to compete with
E. coli in a bacterial competition assay. This is the first
time that this type of systematic mapping has been car-
ried out in Vibrio. Importantly, the mutants provide a
powerful tool for further dissecting the functional role of
VipA/VipB in the V. cholerae T6SS.
The protein stability assay utilizing chloramphenicol to
stop de novo protein synthesis revealed that VipB was very
rapidly degraded in the absence of VipA. This indicates
that VipB degradation may be a potent mechanism used
by T6SS-containing bacteria to regulate the activity of the
secretion system in response to distinct environmental
stimuli. In further support of an important role of en-
vironmental stimuli for the VipA-VipB interaction and
thereby control of T6S, we observed that a high concen-
tration of salt appeared beneficial for the stability of the
complex. High salt (340 mM) is also an important trigger
for the activity of the T6SS of V. cholerae O1 strain A1552
[13], which is a concentration not far from that found in
the normal ocean habitat of Vibrio, i.e. around 500 mM.
Overall, the results on the VipA-VipB interaction
agreed between the B2H and Y2H methods. The mul-
tiple alanine substitution mutants that failed to interact
with VipB, or exhibited intermediate binding, showed
unstable expression of VipB in V. cholerae and E. coli,
indicating a lack of proper interaction with the latter.
Importantly, the failure to interact was not due to pro-
tein instability, since the mutant alleles were shown to
be expressed at wild-type levels in V. cholerae as well as
in the E. coli B2H system.
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but our data indicate that the functional VipA/VipB com-
plex is a prerequisite for the normal function of the T6SS.
It has been suggested to guide effector proteins to the se-
cretion channel, analogous to what has been suggested for
chaperones of type III secretion systems [28,29]. However,
a study aimed to elucidate the essential function of ClpV
for T6S, identified a direct interaction with VipB and re-
vealed a remodeling of the VipA/VipB complex upon
interaction with ClpV [9]. The complex alone appeared as
large, tubular, cogwheel-like structures but these were
dissolved when interacting with ClpV into small com-
plexes. Moreover, no direct interaction was observed be-
tween the VipA/VipB complex and the secreted substrates
Hcp or VgrG2. Thus, these findings suggest that the com-
plex does not direct the secretory proteins for export, but
instead it was proposed that the ClpV-mediated remode-
ling of VipA/VipB controls the dynamics of VipA/VipB
tubules by regulating the number and size of the com-
plexes and ultimately the activity of the T6S apparatus [9].
A follow-up study utilized an immobilized library of
15-mer peptides of VipA and VipB to identify the bind-
ing site between the N-terminus of ClpV and VipA/VipB
[10]. While no VipA binding was identified by this ap-
proach, a few VipB peptides appeared to interact and
two located in the N-terminus of VipB were subjected to
further analysis. The binding was shown to involve a
hydrophobic groove of ClpV, but the interaction was
weak and it was hypothesized that ATP-driven ClpV
hexamerization is important for coupling multiple weak
interactions and to ensure a rather selective binding of
ClpV to the macromolecular complex. These findings
might be reconciled with those we obtained using the
yeast two-hybrid interaction assay. The binding to VipB
may simply be too weak to be revealed by this assay.
Interestingly, the two-hybrid assay did detect binding
between the N-terminus of ClpV and VipA as well as
two VipA homologues encoded by P. aeruginosa and Y.
pseudotuberculosis. This may be a reflection of that the
peptide library used by Pietrosiuk et al. may not be suffi-
cient to reveal an interaction present between the ClpV
N-terminus and intact VipA proteins, since there may
be secondary structures of VipA that allow its binding to
ClpV. Our finding also implies that the VipA-VipB inter-
action with ClpV may be more complicated than previ-
ously anticipated. Although the study by Pietrosiuk et al.
did not detect VipA degradation in a cell-free context,
levels were significantly reduced when intact V. cholerae
bacteria were analyzed, indicating that there may be di-
rect interaction between ClpV and VipA [9].
Altogether, our findings indicate that the VipA/VipB
complex has unique functional constraints and our pre-
vious findings indicate that the constraints are shared by
the homologous complexes in other Gram-negativebacteria. Since VipA-VipB homologues are present in
such a wide variety of pathogens, this interaction offers
a unique and attractive target for the development of
novel antibacterial agents. Future investigations to iden-
tify drugs that block the VipA-VipB interaction could
lead to the development of therapeutics effective against
a wide range of infectious diseases.
Conclusions
VipA and VipB homologues are known to interact in
many Gram-negative pathogens. In V. cholerae, their es-
sential role in the secretion of T6S substrates has been
demonstrated previously. Using site-directed mutagen-
esis within VipA, we demonstrated that a dramatically
diminished interaction to VipB was shown to correlate
with a decrease in VipB stability and a loss of Hcp secre-
tion and rendered the bacterium unable to compete with
Escherichia coli in a competition assay. This confirms
the biological relevance of the VipA-VipB interaction,
which is a prerequisite also for the T6S activity of in-
tracellular pathogens like Francisella tularensis and
Burkholderia cenocepacia. Thus, this conserved inter-
action offers an attractive target for the development of
novel antibacterials.
Methods
Bacterial strains, plasmids and growth conditions
Bacterial strains and plasmids used in this study are listed
in a table [see Additional file 1]. E. coli and V. cholerae
were cultivated on Luria Bertani (LB) agar or broth at 37°C
unless stated otherwise. When necessary, carbenicillin (Cb;
100 μg/ml), kanamycin (Km; 50 μg/ml), chloramphenicol
(Cm; 25 μg/ml), rifampicin (Rif; 100 μg/ml), streptomycin
(Strp; 50 μg/ml) or tetracycline (Tet; 10 μg/ml) were used.
Construction of expression plasmids
Primer combinations and restriction sites used for vector
construction are listed in a table [see Additional file 2].
All PCR amplified fragments were first cloned into the
pCR4-TOPO TA cloning vector (Invitrogen AB) to
facilitate sequencing (Eurofins MWG Operon) before
proceeding with the cloning. Mutated vipA alleles
containing in-frame deletions or codon-usage adapted
alanine substitutions were constructed by overlap PCR
[30]. V. cholerae A1552 chromosomal DNA was used as
template in the PCR reactions, with the exception of the
multiple substitution mutants which were constructed
sequentially using previously generated substitution mu-
tants as template. Thus, the double mutants D104A/
V106A and V110A/L113A were generated using D104A
and V110A respectively as template, the triple mutant
D104A/V106A/V110A was generated using D104A/
V106A as template and the quadruple mutant D104A/
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V106A/ V110A as template.
For trans-complementation studies, PCR amplified 6 ×
HisC tagged vipB or vipA mutants were introduced into
plasmid pMMB66EH [31] to allow expression from the
ptac promoter and transferred into V. cholerae by conju-
gation using S17-1λ pir as donor.
To investigate protein-protein interactions in E. coli,
PCR amplified fragments encoding VipA or mutants
thereof, VipB, full-length or truncated ClpV (first 178
residues), were ligated into plasmids pBRGPω (directs
the synthesis of a Gal11P-ω fusion protein and can be
used to create fusions to the N-terminus of the ω sub-
unit of E. coli RNAP) and pACTR-AP-Zif (directs the
synthesis of the zinc finger DNA-binding domain of
the murine Zif268 protein and can be used to create
fusions to the N-terminus of Zif268) [32]. Plasmids
were introduced into the reporter strain KDZif1ΔZ by
electroporation.
To perform protein-protein interactions studies in
yeast, PCR amplified fragments encoding mutant deriva-
tives of VipA, full-length or truncated ClpV (first 178
residues), were ligated into the GAL4 activation domain
plasmid pGADT7 or the GAL4 DNA-binding domain
plasmid pGBKT7 (Clontech Laboratories, Palo Alto, CA,
USA). To construct pGADT7 variants encoding YPTB1
483 Δ105-114 and PA2365 Δ109-118, the corresponding
alleles were lifted by NdeI/BamHI and NdeI/EcoRI diges-
tion from vectors pJEB582 and pJEB584 [6] respectively,
and introduced into pGADT7. Plasmids were transferred
into strain AH109 or Y187 as described previously [33].
Analysis of T6S protein production and secretion
To induce type VI secretion in V. cholerae A1552 deriva-
tives, bacterial strains were grown in LB medium
containing 340 mM NaCl and samples were taken at
OD600 = 2.0 as described previously [13]. At OD600 = 1.0,
IPTG (Isopropyl β-D-1-thiogalactopyranoside) was ad-
ded at a final concentration of 0.5 mM to induce ex-
pression from the ptac promoter. To assess protein
secretion, TCA precipitated supernatants were analyzed,
while intrabacterial protein levels were determined using
total samples or pelleted bacteria. Protein samples were
separated by SDS-PAGE and analyzed by Western blot
using polyclonal antibodies recognizing VipB (Agrisera,
Vännäs, Sweden) or Hcp [34], while VipA (His6-tagged)
was visualized using monoclonal Anti-His antibodies
(Qiagen, Sollentuna, Sweden). Proteins were visualized
using the Enhanced Chemiluminescence system (ECL)
(Amersham Biosciences, Uppsala, Sweden).
Protein stability
The intrabacterial protein stability assay was adapted from
Feldman and colleagues [35] with some modifications. Inshort,V. cholerae was grown overnight at 37°C in LB, di-
luted 200 × in fresh medium and grown for 1.5 h before
addition of 0.5 mM IPTG. After 2 h, protein synthesis
was stopped by addition of 50 μg/ml chloramphenicol
(corresponds to time zero). Samples were taken out at
different time points and analyzed by Western blot
using antisera recognizing 6 × His or VipB (above) in
combination with ECL.
RNA extraction and qRT-PCR
RNA extraction, qRT-PCR and the sequence of the
primers used have been described elsewhere [36]. For
each sample, the mean cycle threshold of the test tran-
script was normalized to that of tmRNA [36]. Results
were analysed using the delta delta Ct method of ana-
lysis and converted to relative expression ratio (2-ΔΔCt)
for statistical analysis [37], using a paired two-tailed
t-test to compare means. Data is presented as the mean
N-fold change ± standard deviation of 2 independent
experiments where triplicate samples were used.
Bacterial two-hybrid assay (B2H)
KDZif1ΔZ reporter cells were grown overnight at 37°C
in LB with appropriate antibiotics, diluted 100 × in fresh
medium supplemented with antibiotics and 0.5 mM
IPTG. At OD600 = 0.5-0.7, cells were harvested, perme-
abilized with SDS-CHCl3 and assayed for β-galactosidase
activity as described [14]. To determine levels of VipA
mutants or VipB, protein samples were separated by
SDS-PAGE and subjected to Western blot analysis using
polyclonal antibodies recognizing VipA (kind gift from
Professor Axel Mogk) [9] or VipB in combination with
ECL. B2H assays were performed at least three times in
duplicates on separate occasions. A two-sided t-test
with equal variance was used to determine statistical
significance.
Yeast two-hybrid assay (Y2H)
Protein expression analysis of Saccharomyces cerevisiae
lysates and analysis of protein-protein interactions were
performed according to established methods [33]. Spe-
cifically, interactions were determined by growth of yeast
on synthetic dropout minimal agar (Clontech Laboratories)
devoid of tryptophan, leucine (SD-LT) and adenine resul-
ting from ADE2 reporter gene activation. The interactive
potential was confirmed by comparative growth at 25°C,
30°C and 37°C to provide an insight into the relative en-
ergy required for each interaction, and by induction of
two independent reporter genes, HIS3 and lacZ, by grow-
ing yeast on SD-LT agar lacking histidine and in liquid
culture using ONPG (o-Nitrophenyl-beta-D-Galactopyra-
noside (Sigma-Aldrich, St. Louis, MO, USA) as substrate
respectively. Due to an intrinsic leakiness with the HIS3
reporter, 1.5 mM 3-aminotriazole was added to histidine
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MEL1 expression directly on SD-LT plates containing
X-α-Gal (Sigma-Aldrich), yeast was spotted and grown for
2 days before the degree of blue colour development indi-
cative of α-galactsidase activity and X-α-Gal hydrolysis
was scored. Protein expression was verified using anti-
bodies recognizing the activation or DNA-binding domain
of GAL4 (Clontech Laboratories).
E. coli competition assay
Vibrio and E. coli MC4100 (all containing empty
pMMB66EH or vipA-expressing derivates thereof ) were
grown overnight at 37°C in LB medium containing
340 mM NaCl medium and Cb. Next day, strains were
subcultured 1/100 in fresh medium. IPTG was added to
a final concentration of 0.5 mM to V. cholerae strains at
OD600 = 1.0, and upon reaching OD600 = 2.0, Vibrio was
mixed at a 3 to 1 ratio with E. coli of OD600 = 0.2,
followed by rigorous vortexing for 1 min. As controls,
E. coli was also mixed with LB (LB control and inoculum
control). The inoculum control, which was used to esti-
mate the original numbers of E. coli in the assay, was di-
luted and spread immediately as described below, while
100 μL of the LB control or the V. cholerae - E. coli mix-
tures were incubated on 0.22 μM nitrocellulose filters
(Millipore) placed on well-dried LA plates supplemented
with 340 mM NaCl, Cb and IPTG. After 5 h of incuba-
tion at 37°C, bacterial cells were harvested from the filter
and serial dilutions generated and spread on LA plates
containing Strp (selects for E. coli only) in triplicates.
Next day, the number of surviving E. coli was counted.
The ability of Δhcp, ΔvipA and ΔvipA expressing wild-
type or mutated VipA in trans to compete with E. coli
was compared.
Additional files
Additional file 1: Strains and plasmids used in this study.
Additional file 2: Oligonucleotides used in this study.
Abbreviations
T6S: Type VI secretion; T6SS: Type VI secretion system; T3SS: Type III secretion
system; T4SS: Type IV secretion system; Hcp: Hemolysin co-regulated protein;
VgrG: Valine-glycine repeat protein G; B2H: Bacterial 2-hybrid assay;
Y2H: Yeast 2-hybrid assay; TCP: Toxin co-regulated pili; CT: Cholera toxin;
IPTG: Isopropyl β-D-1-thiogalactopyranoside; ECL: Enhanced
chemiluminescence system.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JEB generated the constructs and strains used, performed most of the
analyses, contributed to the design of the study and drafted the manuscript.
TI performed the qRT-PCR and contributed to the protein sample
preparations and bacterial competition assays. SNW contributed to the
design of the study. AS contributed to the design of the study and drafted
the manuscript. All authors read and approved the final manuscript.Acknowledgements
This work was supported by grants 2006–3426 (to JEB), 2006–2877 and
2009–5026 (to AS) and 2010–3073 (to SNW) from the Swedish Research
Council and a grant from the Medical Faculty, Umeå University, Umeå,
Sweden. The work was performed in part at the Umeå Centre for Microbial
Research (UCMR).
Author details
1Department of Clinical Microbiology, Clinical Bacteriology, Umeå University,
Umeå SE-901 85, Sweden. 2Department of Molecular Microbiology, Umeå
University, Umeå SE-901 87, Sweden. 3Laboratory for Molecular Infection
Medicine Sweden (MIMS), Umeå University, Umeå SE-901 87, Sweden.
Received: 24 October 2012 Accepted: 30 April 2013
Published: 3 May 2013References
1. Jani AJ, Cotter PA: Type VI secretion: not just for pathogenesis anymore.
Cell Host Microbe 2010, 8(1):2–6.
2. Schwarz S, Hood RD, Mougous JD: What is type VI secretion doing in all
those bugs? Trends Microbiol 2010, 18(12):531–537.
3. Hayes CS, Aoki SK, Low DA: Bacterial contact-dependent delivery systems.
Annu Rev Genet 2010, 44:71–90.
4. Boyer F, Fichant G, Berthod J, Vandenbrouck Y, Attree I: Dissecting the
bacterial type VI secretion system by a genome wide in silico analysis:
what can be learned from available microbial genomic resources?
BMC Genomics 2009, 10(104):104.
5. Bingle LE, Bailey CM, Pallen MJ: Type VI secretion: a beginner’s guide.
Curr Opin Microbiol 2008, 11(1):3–8.
6. Bröms JE, Lavander M, Sjöstedt A: A conserved α-helix essential for a type
VI secretion-like system of Francisella tularensis. J Bacteriol 2009, 6:6.
7. Aubert D, MacDonald DK, Valvano MA: BcsKC is an essential protein for
the type VI secretion system activity in Burkholderia cenocepacia that
forms an outer membrane complex with BcsLB. J Biol Chem 2010,
285(46):35988–35998.
8. Basler M, Pilhofer M, Henderson GP, Jensen GJ, Mekalanos JJ: Type VI secretion
requires a dynamic contractile phage tail-like structure. Nature 2012,
483(7388):182–186.
9. Bönemann G, Pietrosiuk A, Diemand A, Zentgraf H, Mogk A: Remodelling of
VipA/VipB tubules by ClpV-mediated threading is crucial for type VI
protein secretion. EMBO J 2009, 28(4):315–325.
10. Pietrosiuk A, Lenherr ED, Falk S, Bonemann G, Kopp J, Zentgraf H, Sinning I,
Mogk A: Molecular basis for the unique role of the AAA + chaperone
ClpV in type VI protein secretion. J Biol Chem 2011, 286(34):30010–30021.
11. Mougous JD, Cuff ME, Raunser S, Shen A, Zhou M, Gifford CA, Goodman AL,
Joachimiak G, Ordonez CL, Lory S, et al: A virulence locus of Pseudomonas
aeruginosa encodes a protein secretion apparatus. Science 2006,
312(5779):1526–1530.
12. Pukatzki S, Ma AT, Sturtevant D, Krastins B, Sarracino D, Nelson WC,
Heidelberg JF, Mekalanos JJ: Identification of a conserved bacterial
protein secretion system in Vibrio cholerae using the Dictyostelium host
model system. Proc Natl Acad Sci U S A 2006, 103(5):1528–1533.
13. Ishikawa T, Sabharwal D, Bröms J, Milton DL, Sjöstedt A, Uhlin BE, Wai SN:
Pathoadaptive conditional regulation of the type VI secretion system in
Vibrio cholerae O1 strains. Infect Immun 2012, 80(2):575–584.
14. Dove SL, Hochschild A: A bacterial two-hybrid system based on
transcription activation. Methods Mol Biol 2004, 261:231–246.
15. Charity JC, Costante-Hamm MM, Balon EL, Boyd DH, Rubin EJ, Dove SL:
Twin RNA polymerase-associated proteins control virulence gene
expression in Francisella tularensis. PLoS Pathog 2007, 3(6):e84.
16. Hood RD, Singh P, Hsu F, Guvener T, Carl MA, Trinidad RR, Silverman JM,
Ohlson BB, Hicks KG, Plemel RL, et al: A type VI secretion system of
Pseudomonas aeruginosa targets a toxin to bacteria. Cell Host Microbe
2010, 7(1):25–37.
17. Murdoch SL, Trunk K, English G, Fritsch MJ, Pourkarimi E, Coulthurst SJ: The
opportunistic pathogen Serratia marcescens utilizes type VI secretion to
target bacterial competitors. J Bacteriol 2011, 193(21):6057–6069.
18. Russell AB, Hood RD, Bui NK, LeRoux M, Vollmer W, Mougous JD: Type VI
secretion delivers bacteriolytic effectors to target cells. Nature 2011,
475(7356):343–347.
Bröms et al. BMC Microbiology 2013, 13:96 Page 12 of 12
http://www.biomedcentral.com/1471-2180/13/9619. Schwarz S, West TE, Boyer F, Chiang WC, Carl MA, Hood RD, Rohmer L,
Tolker-Nielsen T, Skerrett SJ, Mougous JD: Burkholderia type VI secretion
systems have distinct roles in eukaryotic and bacterial cell interactions.
PLoS Pathog 2010, 6(8):e1001068.
20. Zheng J, Ho B, Mekalanos JJ: Genetic analysis of anti-amoebae and anti-
bacterial activities of the type VI secretion system in Vibrio cholerae. PLoS
One 2011, 6(8):e23876.
21. MacIntyre DL, Miyata ST, Kitaoka M, Pukatzki S: The Vibrio cholerae type VI
secretion system displays antimicrobial properties. Proc Natl Acad Sci U S
A 2010, 107(45):19520–19524.
22. Miller VL, Taylor RK, Mekalanos JJ: Cholera toxin transcriptional activator
toxR is a transmembrane DNA binding protein. Cell 1987, 48(2):271–279.
23. Taylor RK, Miller VL, Furlong DB, Mekalanos JJ: Use of phoA gene fusions to
identify a pilus colonization factor coordinately regulated with cholera
toxin. Proc Natl Acad Sci U S A 1987, 84(9):2833–2837.
24. Ma AT, Mekalanos JJ: In vivo actin cross-linking induced by Vibrio cholerae
type VI secretion system is associated with intestinal inflammation. Proc Natl
Acad Sci U S A 2010, 107(9):4365–4370.
25. Zheng J, Shin OS, Cameron DE, Mekalanos JJ: Quorum sensing and a global
regulator TsrA control expression of type VI secretion and virulence in
Vibrio cholerae. Proc Natl Acad Sci U S A 2010, 107(49):21128–21133.
26. Pukatzki S, Ma AT, Revel AT, Sturtevant D, Mekalanos JJ: Type VI secretion
system translocates a phage tail spike-like protein into target cells where it
cross-links actin. Proc Natl Acad Sci U S A 2007, 104(39):15508–15513.
27. Ma AT, McAuley S, Pukatzki S, Mekalanos JJ: Translocation of a Vibrio
cholerae type VI secretion effector requires bacterial endocytosis by host
cells. Cell Host Microbe 2009, 5(3):234–243.
28. Cascales E: The type VI secretion toolkit. EMBO Rep 2008, 9(8):735–741.
29. Filloux A, Hachani A, Bleves S: The bacterial type VI secretion machine: yet
another player for protein transport across membranes. Microbiology
2008, 154(Pt 6):1570–1583.
30. Horton RM, Pease LR: Recombination and mutagenesis of DNA sequences
using PCR. In Directed Mutagenesis: a Practical approach. Edited by
McPherson M. New York: Oxford University Press; 1991:217–247.
31. Fürste JP, Pansegrau W, Frank R, Blocker H, Scholz P, Bagdasarian M, Lanka E:
Molecular cloning of the plasmid RP4 primase region in a multi-host-range
tacP expression vector. Gene 1986, 48(1):119–131.
32. Vallet-Gely I, Donovan KE, Fang R, Joung JK, Dove SL: Repression of phase-
variable cup gene expression by H-NS-like proteins in Pseudomonas
aeruginosa. Proc Natl Acad Sci U S A 2005, 102(31):11082–11087.
33. Francis MS, Aili M, Wiklund ML, Wolf-Watz H: A study of the YopD-lcrH
interaction from Yersinia pseudotuberculosis reveals a role for hydrophobic
residues within the amphipathic domain of YopD. Mol Microbiol 2000,
38(1):85–102.
34. Ishikawa T, Rompikuntal PK, Lindmark B, Milton DL, Wai SN: Quorum
sensing regulation of the two hcp alleles in Vibrio cholerae O1 strains.
PLoS One 2009, 4(8):e6734.
35. Feldman MF, Muller S, Wuest E, Cornelis GR: SycE allows secretion of
YopE-DHFR hybrids by the Yersinia enterocolitica type III Ysc system.
Mol Microbiol 2002, 46(4):1183–1197.
36. Valeru SP, Rompikuntal PK, Ishikawa T, Vaitkevicius K, Sjoling A, Dolganov N,
Zhu J, Schoolnik G, Wai SN: Role of melanin pigment in expression of
Vibrio cholerae virulence factors. Infect Immun 2009, 77(3):935–942.
37. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method.
Methods 2001, 25(4):402–408.
38. James P, Halladay J, Craig EA: Genomic libraries and a host strain designed
for highly efficient two-hybrid selection in yeast. Genetics 1996,
144(4):1425–1436.
doi:10.1186/1471-2180-13-96
Cite this article as: Bröms et al.: A functional VipA-VipB interaction is
required for the type VI secretion system activity of Vibrio cholerae O1
strain A1552. BMC Microbiology 2013 13:96.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
